Cargando…

Standardization of PD-L1 immunohistochemistry

Detalles Bibliográficos
Autores principales:	Martinez-Morilla, Sandra, Moutafi, Myrto, Rimm, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860739/ https://www.ncbi.nlm.nih.gov/pubmed/34508229 http://dx.doi.org/10.1038/s41379-021-00917-4

Ejemplares similares

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray
por: Martinez-Morilla, Sandra, et al.
Publicado: (2019)

Digital quantitative assessment of PD-L1 using digital spatial profiling
por: Gupta, Swati, et al.
Publicado: (2020)

Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry
por: MacNeil, Tyler, et al.
Publicado: (2020)

Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry
por: Siddiqui, Summar, et al.
Publicado: (2010)

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2023)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
por: Moutafi, Myrto K, et al.
Publicado: (2022)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Improving the State of the Science of Immunohistochemistry: The Histochemical Society’s Standards of Practice
por: Baskin, Denis G., et al.
Publicado: (2014)

Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry
por: Inge, L.J., et al.
Publicado: (2020)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

PD-L1/PD-1: new kid on the “immune metabolic” block
por: Qorraj, Mirjeta, et al.
Publicado: (2017)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Accurate expression of PD‐L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry
por: Shinchi, Yusuke, et al.
Publicado: (2019)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023)

Association between low estrogen receptor positive breast cancer and staining performance
por: Caruana, Dennis, et al.
Publicado: (2020)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review
por: Koomen, Bregje M, et al.
Publicado: (2020)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Does the gut microbiota play a key role in PD-1/PD-L1 blockade therapy?
por: Watanabe, Satoshi, et al.
Publicado: (2020)

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
por: Dai, Meng-Yuan, et al.
Publicado: (2022)

Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
por: Aung, Thazin Nwe, et al.
Publicado: (2022)

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
por: Huang, Richard S. P., et al.
Publicado: (2021)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2020)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j376a54tdkaku5dtief64j3ekt